FDA panel affirms safety of Pfizer's Celebrex

FDA's Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 15-5 that the Phase IV CV outcomes PRECISION trial showed that Celebrex celecoxib from Pfizer Inc. (NYSE:PFE) had comparable cardiovascular safety to non-selective NSAIDS naproxen and ibuprofen.

Celebrex is an NSAID that selectively inhibits cyclooxygenase-2 (COX-2)...